There are 2867 resources available
1362MO - Pembrolizumab + olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study
Presenter: Evan Yu
Session: Mini Oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
Biliary tract cancer: Discussion / Q&A
Presenter: All Speakers
Session: ESMO Clinical Practice Guidelines session 1
Resources:
Webcast
974MO - 5-year update from KEYNOTE-407: Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC)
Presenter: Silvia Novello
Session: Mini Oral session: NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1363MO - Cabazitaxel every 2 weeks versus every 3 weeks in older patients with metastatic castration-resistant prostate cancer (mCRPC): The CABASTY randomized phase III trial
Presenter: Stephane Oudard
Session: Mini Oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA59, 973MO and 974MO
Presenter: Mary O'Brien
Session: Mini Oral session: NSCLC, metastatic
Resources:
Slides
Webcast
1364MO - Preliminary phase II results of the CYPIDES study of ODM-208 in metastatic castration-resistant prostate (mCRPC) cancer patients
Presenter: Karim Fizazi
Session: Mini Oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA65, 1362MO, 1363MO and 1364MO
Presenter: Martijn Lolkema
Session: Mini Oral session: GU tumours, prostate
Resources:
Slides
Webcast
Presentation of case/condition
Presenter: Inga-Marie Schaefer
Session: Localized extremity STS: Looking beyond surgery
Resources:
Slides
Webcast
Introduction by the chair
Presenter: Sandra Schmitz
Session: What is the optimal approach to managing intermediate stage HPV positive oropharyngeal carcinoma?
Resources:
Slides
Webcast
Isolated limb perfusion
Presenter: Sylvie Bonvalot
Session: Localized extremity STS: Looking beyond surgery
Resources:
Slides
Webcast